Known targets — ChEMBL curated mechanism
BLKEPHB4FGFR1FGFR2FGRFLT1FRKFYNHCKKDRLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Tg100-801. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YES1 known ✓ | P07947 | 6/20 | 1.00 |
| ▸ | EPHB4 known ✓ | P54760 | 6/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 5/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 18/20 | 0.89 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.76 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.75 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 0.68 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.68 |
| ▸ | FYN known ✓ | P06241 | 1/20 | 0.66 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.66 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 6/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tg100-801 SCHEMBL29941250 | 1.00 | YES1 (1.00) | YES1EPHB4ABL1PDGFRBLCK | |
| Tg100-801 SCHEMBL29363355 | 0.99 | YES1 (0.99) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL4272189 | 0.94 | SRC (1.00) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL12198198 | 0.93 | ABL1 (0.87) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL4272203 | 0.91 | SRC (1.00) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL12198199 | 0.89 | SRC (0.86) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL4268136 | 0.89 | SRC (1.00) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL4264210 | 0.89 | SRC (0.85) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL12198202 | 0.89 | SRC (1.00) | YES1EPHB4ABL1PDGFRBLCK | |
| SCHEMBL4265021 | 0.87 | SRC (1.00) | YES1EPHB4ABL1PDGFRBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260116975-A1 | USE OF COMBINATION OF ANTI-PD-1 ANTIBODY AND VEGFR INHIBITOR IN PREPARATION OF DRUG FOR TREATING CANCERS | SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4714966-A2 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | Cero Therapeutics Holdings, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4376874-B1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | TARGEGEN INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | TARGEGEN INC. | 2011-10-06 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | YES1 237/4885EPHB4 2376/4885PDGFRB 221/4885 |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | ARG1, ARG2, PDE6D | YES1 1020/4885EPHB4 4857/4885PDGFRB 1428/4885 |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | EGFR, ERBB2, HAVCR2 | YES1 98/4885EPHB4 1865/4885PDGFRB 689/4885 |
| US-20260116975-A1 | USE OF COMBINATION OF ANTI-PD-1 ANTIBODY AND VEGFR INHIBITOR IN PREPARATION OF DRUG FOR TREATING CANCERS | PDCD1, PDCD1LG2, FLT1 | YES1 157/4885EPHB4 4357/4885PDGFRB 397/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | YES1 237/4885EPHB4 2376/4885PDGFRB 221/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | YES1 147/4885EPHB4 450/4885PDGFRB 632/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | YES1 1304/4885EPHB4 2921/4885PDGFRB 2794/4885 |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | AQP3, AQP1, AQP4 | YES1 3099/4885EPHB4 763/4885PDGFRB 2591/4885 |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CD47, TNFSF10, CD2 | YES1 422/4885EPHB4 414/4885PDGFRB 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.